Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome
Zoellner A, Fritsch S, Prevalsek D et al.
Key Points:
Induction chemotherapy with clofarabine (5x30 mg/m² IV), followed by 3 days of rest.
Median neutrophil engraftment achieved on day 21 (range 14-36): platelet engraftment on day 30 (range 18-115). Donor chimerism detected in 16 patients on day +30.
Acute GvHD grade II-IV observed in 31%, chronic GvHD occurred in 21%.
Implications:
- Combination induction-chemotherapy with clofarabine and HLA-haploidentical HSCT using RIC feasible, anti-lymphoid activity achieved in patients with advanced non-remission lymphoma.
View the original abstract on the ASH website.
